Wednesday, June 21 • 10:30am - 11:45am
#326: Optimizing Early Clinical Strategies to Support Breakthrough Therapy Designation

Sign up or log in to save this to your schedule and see who's attending!

Component Type: Forum
Level: Intermediate
CE: CME 1.25; IACET 1.25; RN 1.25

Preliminary clinical evidence showing substantial improvement over existing therapies on at least one clinically significant outcome is required to qualify for breakthrough therapy designation. This session will focus on how to optimize chances of early breakthrough therapy designation and developments in the breakthrough therapy space.

Learning Objectives

Describe the key considerations and challenges in the design of early clinical trials to provide sufficient evidence of early benefit; Discuss successful case examples of novel therapies that have never before received FDA approval; Learn about developing issues related breakthrough therapy designation.


Alexander Varond, JD


Breakthrough Therapy Designation: Optimizing Early Clinical Strategies to Support Breakthrough Therapy Designation
Alexander Varond, JD

Patient Advocacy Perspective
Jeff Allen, PhD

FDA and Office of Tissues and Advanced Therapies Perspective
Ilan Irony, MD

avatar for Alexander Varond

Alexander Varond

Associate, Goodwin Procter LLP
Alexander J. Varond works on drug development and medical devices, advertising and promotion, and enforcement issues. He counsels clients on drug development matters such as clinical trial design, REMS, orphan drug designation, formal dispute resolution, and patent and exclusivity... Read More →

avatar for Jeff Allen

Jeff Allen

President and Chief Executive Officer, Friends of Cancer Research
Jeff Allen is President and CEO of Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, DC that drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments... Read More →
avatar for Ilan Irony

Ilan Irony

Deputy Director, DCEPT, OTAT, CBER, FDA
After training at UCSF and NIH and years of practice in Internal Medicine and Endocrinology, Dr. Irony joined FDA CBER in 2000 as a clinical reviewer. He also worked in the Endocrine Division in CDER as a reviewer and team leader. In 2011, he returned to CBER first as branch chief... Read More →

Wednesday June 21, 2017 10:30am - 11:45am
S401a McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616